Seaport Therapeutics, Inc. Common Stock (SPTX)

PHARMACEUTICAL PREPARATIONS

Headquarters: United States
Market Cap: $1.3B

About Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

SentiSense also tracks daily options readings for Seaport Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.

Seaport Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.